DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 7, 2024

Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers CMS Reimbursement 105

DAIC

JULY 25, 2024

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

GEMMS

SEPTEMBER 12, 2023

These features are pivotal in ensuring accurate diagnoses, streamlined workflows, and improved patient outcomes. Streamlined Billing and Coding Billing and coding in cardiology are complex endeavors involving intricate procedures, codes, and reimbursements.

Echocardiogram 52

Echocardiogram Reimbursement Patient Care Article 52

GEMMS

JANUARY 2, 2024

Key features include: Compliance Under Appropriate Use Criteria (AUC) – GEMMS ONE meets CMS standards and requirements by including an AUC orders module, part of its integrated system. This enables early intervention, minimizes hospital admissions, and helps improve patient outcomes.

Document 52

Document Patient Care Private Practice CMS 52